Apatinib in Refractory Colorectal Cancer

Exclusion Criteria

• •Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)\].
• •Participants of other clinical trial within 4 weeks.
• •Diseases which will impact the absorption of apatinib, eg. dysphagia, chronic diarrhea, bowl obstruction
• •Hemorrhage events of ≥grade 3 within 4 weeks.
• •known central nervous system metastasis.
• •Uncontrolled hypertension. (Systolic blood pressure 140 mmHg or diastolic pressure 90 mmHg despite optimal medical management). Unstable angina,congestive heart failure,Myocardial infarction, Cardiac arrhythmias requiring anti-arrhythmic therapy.
• •urine protein ≥++ and 24h urine protein more than 1.0g.
• •Chronically green wound or bone fracture.
• •Arterial or venous thrombotic or embolic events.
• •Tumor invading important blood vessel with high risk of severe hemorrhage.
• •Abnormal coagulation function.
• •thromboemboli events within 6 months.